Two Indian Nationals Indicted in Alleged Counterfeit Ozempic Smuggling Scheme

Two Indian nationals have been indicted in the United States over an alleged international scheme to smuggle and sell counterfeit Ozempic, according to the U.S. Department of Justice (DOJ).

The case involves Swapnadip Roy, 33, and Vicky Ramancha, 37, whom prosecutors allege obtained counterfeit versions of the diabetes and weight-management drug from unauthorized sources in China and supplied them to U.S. distributors at deeply discounted prices.

The indictment was unsealed in June 2026, while the DOJ announced the charges publicly on September 29. Roy was extradited from Italy and appeared in federal court in Tampa, Florida, on Tuesday. Ramancha remains at large, according to the DOJ.

The case highlights a growing challenge for pharmaceutical companies and regulators: as demand for popular GLP-1 medicines rises, counterfeit versions can create both patient-safety risks and financial damage across legitimate drug supply chains.

What the DOJ Alleges

According to court documents, the alleged activity took place from approximately July 2023 through April 2024.

Prosecutors say Roy, Ramancha and their co-conspirators obtained counterfeit Ozempic from unauthorized sources in China before selling the products to U.S. distributors.

The alleged counterfeit products were designed to resemble authentic medicines. The DOJ says they included counterfeit packaging, package inserts, pen labels and needles intended to make downstream buyers believe they were purchasing genuine Ozempic authorized by its manufacturer.

The products were allegedly sold at substantially discounted prices, potentially making them attractive to distributors looking for cheaper supplies of a high-demand medicine.

The DOJ also says the alleged distribution continued after the U.S. Food and Drug Administration seized some counterfeit Ozempic in December 2023 and issued a public warning.

These allegations have not been proven in court.

Charges Carry a Potential Maximum of 71 Years

Roy and Ramancha face several federal charges.

The indictment includes:

• One count of conspiracy to commit smuggling and defraud the United States

• Three counts of smuggling

• Two counts involving selling counterfeit drugs and holding counterfeit drugs for sale

The DOJ says each defendant could face a maximum potential sentence of 71 years in prison if convicted. That figure represents the statutory maximum across the charges and does not mean either defendant will necessarily receive such a sentence.

Roy pleaded not guilty following his extradition from Italy, Reuters reported. Ramancha remains outside U.S. custody.

The DOJ explicitly states that an indictment is an allegation and that defendants are presumed innocent unless proven guilty beyond a reasonable doubt.

Why Counterfeit Ozempic Is a Serious Supply-Chain Risk

Counterfeit medicines present a different risk from ordinary unauthorized imports because consumers may not know that the product is fake.

The FDA says counterfeit drugs can contain the wrong ingredients, too little or too much active ingredient, no active ingredient, or potentially harmful substances.

That makes the issue particularly important for injectable medicines.

Ozempic contains semaglutide and is an injectable prescription medicine. Authentic Ozempic is manufactured by Novo Nordisk, which has become one of the world's most prominent pharmaceutical companies because of strong demand for its GLP-1 medicines.

A counterfeit product that looks authentic can therefore create risks well beyond lost sales. Patients could potentially receive an ineffective or unsafe product while believing they are following a legitimate treatment.

For pharmacies, distributors and manufacturers, counterfeit products can also increase compliance costs and force additional monitoring of supply chains.

FDA Had Already Warned About Counterfeit Ozempic

The latest case is not the first time U.S. authorities have warned about fake Ozempic.

The FDA says it is aware of counterfeit Ozempic being marketed in the United States and continues to investigate suspected counterfeit medicines. The agency has also warned consumers about illegally marketed versions of GLP-1 drugs, including semaglutide and tirzepatide.

The agency recommends that consumers obtain prescription medicines through legitimate, state-licensed pharmacies.

That warning is particularly relevant as online pharmaceutical sales expand. Consumers searching for lower prices can encounter websites or sellers offering medicines outside conventional pharmacy channels, making verification of product authenticity more difficult.

The Case Comes as GLP-1 Demand Remains Strong

Ozempic belongs to the broader GLP-1 drug category, a market that has expanded rapidly because of the medicines' use in treating type 2 diabetes and, for certain drugs, managing obesity.

The popularity of these medicines has created enormous commercial opportunities for pharmaceutical companies, but it has also created incentives for counterfeiters.

For legitimate manufacturers, the problem is therefore not simply about protecting brand names. It involves protecting the integrity of the pharmaceutical distribution system.

Novo Nordisk has invested heavily in expanding its GLP-1 manufacturing capacity as demand for semaglutide products has increased. Competitors, including Eli Lilly, are also expanding their presence in the rapidly growing obesity-drug market.

As the market becomes larger, counterfeiters have a larger potential customer base to target.

What the Case Means for Novo Nordisk and the Pharmaceutical Industry

The indictment does not appear to represent a direct allegation against Novo Nordisk. Instead, it concerns individuals prosecutors say were involved in distributing counterfeit products that were made to appear authentic.

For Novo Nordisk, counterfeit Ozempic nevertheless represents a potential brand and supply-chain issue.

The company and other drugmakers have an interest in ensuring that patients receive medicines through authorized channels. Counterfeit products can undermine consumer confidence and complicate efforts to distinguish legitimate supply from illicit products.

The broader pharmaceutical industry also faces a similar challenge with high-demand medicines.

As online commerce becomes more integrated with healthcare, regulators and manufacturers must monitor a larger number of distribution channels. Enforcement actions such as the Florida case can serve as part of that broader effort.

What Investors Should Watch

For investors following Novo Nordisk and the wider GLP-1 industry, the most important issue is not the individual criminal case alone but what it says about the market surrounding high-demand medicines.

Several areas are worth monitoring:

Regulatory enforcement: Further FDA and DOJ actions could reveal the scale of counterfeit activity involving GLP-1 medicines.

Supply-chain security: Manufacturers and distributors may need additional authentication and tracking systems as counterfeit activity evolves.

Online pharmaceutical sales: Growth in online medicine purchases could create both legitimate distribution opportunities and additional channels for illicit sellers.

Consumer affordability: Large price differences between legitimate and counterfeit products can create incentives for consumers and intermediaries to seek unauthorized sources.

Demand for GLP-1 medicines: Continued demand increases the economic incentive for counterfeiters, particularly where supply is constrained or legitimate treatment remains expensive.

Investors should also distinguish between counterfeit-drug enforcement and the underlying commercial performance of Novo Nordisk or the GLP-1 market. A single criminal case does not by itself establish a material change in a company's earnings outlook.

Conclusion

The U.S. Justice Department has charged two Indian nationals in an alleged cross-border scheme involving counterfeit Ozempic sourced from China and sold to U.S. distributors. Prosecutors say the products were packaged and labeled to resemble genuine medicine, and allege that distribution continued after an FDA seizure and warning.

The case underscores a wider issue facing the fast-growing GLP-1 pharmaceutical market: strong demand can create opportunities not only for legitimate drugmakers but also for counterfeit networks.

The next developments to watch are the court proceedings against Roy, efforts to locate Ramancha, and any additional enforcement or regulatory action involving counterfeit GLP-1 medicines.

Follow AIViralHub for more pharmaceutical, healthcare, business and global market updates.

This article is for informational and educational purposes only and should not be considered investment advice.